TWELVE-MONTH INTERIM ANALYSIS OF EFFICACY AND SAFETY OF GIVOSIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR ACUTE HEPATIC PORPHYRIA, IN THE ENVISION OPEN LABEL EXTENSION

• R. Marchi,
• L. Duarte,
• S. E,
• B. M,
• R. Dc,
• S. P,
• S. U,
• A.P. P,
• B. Dm,
• E. Al,
• K. S,
• P. C,
• P. Jd

Affiliations

R. Marchi

Alnylam Brasil Farmacêutica Ltda, São Paulo, SP, Brazil

L. Duarte

Alnylam Brasil Farmacêutica Ltda, São Paulo, SP, Brazil

S. E

Porphyria Centre Sweden, Centre for Inherited Metabolic Diseases, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

B. M

Icahn School of Medicine at Mt. Sinai, New York, United States

R. Dc

King's College Hospital, London, United Kingdom

S. P

King's College Hospital, London, United Kingdom

S. U

Klinikum Chemnitz, Chemnitz, Germany

A.P. P

Hospital Clinic Barcelona, Barcelona, Spain

B. Dm

University of California, San Francisco, United States

E. Al

Alnylam Brasil Farmacêutica Ltda, São Paulo, SP, Brazil

K. S

University of Washington, Seattle, United States

P. C

University of Utah, Salt Lake City, United States

P. Jd

University of Utah, Salt Lake City, United States